Literature DB >> 1751031

(-)-Deprenyl can induce soluble superoxide dismutase in rat striata.

A Clow1, T Hussain, V Glover, M Sandler, D T Dexter, M Walker.   

Abstract

(-)-Deprenyl (0.25 or 2 mg/kg) or saline was injected daily into male Wistar rats for 3 weeks. The striata were dissected out and soluble and particulate superoxide dismutase activity measured. (-)-Deprenyl at 2 mg/kg induced a significant increase in the soluble but not the particulate form of the enzyme. The possibility that this action contributes to the ability of (-)-deprenyl to retard nigral degeneration in man and prolong life in rats is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751031     DOI: 10.1007/bf01250378

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  14 in total

1.  Superoxide dismutase-like activity in the Parkinson's disease brain.

Authors:  R J Marttila; M Viljanen; E Toivonen; H Lorentz; U K Rinne
Journal:  Adv Neurol       Date:  1990

2.  Superoxide dismutase and Parkinson's disease.

Authors:  I Ceballos; M Lafon; F Javoy-Agid; E Hirsch; A Nicole; P M Sinet; Y Agid
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

3.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

4.  Maintenance on L-deprenyl prolongs life in aged male rats.

Authors:  N W Milgram; R J Racine; P Nellis; A Mendonca; G O Ivy
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

5.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

6.  (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

7.  Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl.

Authors:  J Knoll; J Dallo; T T Yen
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

8.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

9.  The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.

Authors:  C Braestrup; H Andersen; A Randrup
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

10.  The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

Authors:  J Knoll
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

View more
  4 in total

1.  Pergolide can induce soluble superoxide dismutase in rat striata.

Authors:  A Clow; T Hussain; V Glover; M Sandler; M Walker; D Dexter
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Prolongation of life in an experimental model of aging in Drosophila melanogaster.

Authors:  R G Jordens; M D Berry; C Gillott; A A Boulton
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

4.  Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease.

Authors:  Hanxiang Liu; Xianwen Wei; Wen Yang; Gavin P Reynolds
Journal:  J Neural Transm (Vienna)       Date:  2019-12-14       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.